Aptus Capital Advisors LLC Grows Holdings in Eli Lilly and Company $LLY

Key Points

• Aptus Capital Advisors LLC increased its position in Eli Lilly and Company by 10.6%, now owning 48,867 shares valued at approximately $40.36 million.
• Insider activity includes EVP Daniel Skovronsky purchasing 1,000 shares at $634.40 each, raising his total ownership to 137,660 shares worth about $87.33 million.
• Eli Lilly's latest quarterly earnings report showed an EPS of $6.31, surpassing estimates and indicating a 37.6% year-over-year revenue increase to $15.56 billion.

Aptus Capital Advisors LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,867 shares of the company's stock after acquiring an additional 4,687 shares during the period. Aptus Capital Advisors LLC's holdings in Eli Lilly and Company were worth $40,359,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Watts Gwilliam & Co. LLC grew its stake in Eli Lilly and Company by 119.7% during the first quarter. Watts Gwilliam & Co. LLC now owns 3,708 shares of the company's stock valued at $3,063,000 after acquiring an additional 2,020 shares in the last quarter. Granite Harbor Advisors Inc. lifted its position in Eli Lilly and Company by 67.9% during the first quarter. Granite Harbor Advisors Inc. now owns 2,084 shares of the company's stock valued at $1,721,000 after purchasing an additional 843 shares during the last quarter. Brooklyn Investment Group lifted its position in Eli Lilly and Company by 32.4% during the first quarter. Brooklyn Investment Group now owns 6,881 shares of the company's stock valued at $5,682,000 after purchasing an additional 1,685 shares during the last quarter. Valley Brook Capital Group Inc. lifted its position in Eli Lilly and Company by 2.9% during the first quarter. Valley Brook Capital Group Inc. now owns 1,582 shares of the company's stock valued at $1,307,000 after purchasing an additional 45 shares during the last quarter. Finally, Mill Creek Capital Advisors LLC lifted its position in Eli Lilly and Company by 49.9% during the first quarter. Mill Creek Capital Advisors LLC now owns 613 shares of the company's stock valued at $506,000 after purchasing an additional 204 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.8%

NYSE:LLY traded up $5.5170 during midday trading on Tuesday, reaching $703.5670. 5,929,987 shares of the stock traded hands, compared to its average volume of 6,686,759. The company has a fifty day moving average of $760.97 and a 200 day moving average of $793.02. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $972.53. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market capitalization of $665.90 billion, a P/E ratio of 45.98, a PEG ratio of 0.97 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the business posted $3.92 EPS. The firm's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is presently 39.22%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on LLY. Leerink Partners restated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. UBS Group lowered their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, Morgan Stanley restated an "overweight" rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average price target of $950.17.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.